Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Classic Hodgkin Lymphoma”

64 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 64 results

Testing effectiveness (Phase 2)Study completedNCT02824029
What this trial is testing

Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin LymphomaRecurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Barbara Ann Karmanos Cancer Institute 28
Testing effectiveness (Phase 2)Study completedNCT04052997
What this trial is testing

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Relapsed Hodgkin LymphomaRefractory Hodgkin Lymphoma
ADC Therapeutics S.A. 117
Testing effectiveness (Phase 2)Study completedNCT03739619
What this trial is testing

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Who this might be right for
Recurrent Hodgkin LymphomaRefractory Hodgkin LymphomaClassical Hodgkin Lymphoma+1 more
Emory University 3
Early research (Phase 1)Ended earlyNCT01900496
What this trial is testing

Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

Who this might be right for
Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 6
Testing effectiveness (Phase 2)UnknownNCT04026269
What this trial is testing

Clinical Efficacy of MOAP Regimen for Relapsed/Refractory cHL as a Rescue Therapy After DP Regimen

Who this might be right for
Hodgkin Lymphoma
Han weidong 30
Early research (Phase 1)Study completedNCT03229278
What this trial is testing

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Who this might be right for
LymphomaMetastatic Malignant Solid NeoplasmMetastatic Melanoma+26 more
Rutgers, The State University of New Jersey 14
Early research (Phase 1)Study completedNCT00439361
What this trial is testing

Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma

Who this might be right for
Hodgkin LymphomaLymphoma
M.D. Anderson Cancer Center 14
Not applicableEnded earlyNCT00301860
What this trial is testing

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Who this might be right for
LeukemiaLymphoma
University of California, San Francisco 8
Large-scale testing (Phase 3)WithdrawnNCT05711628
What this trial is testing

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT05243693
What this trial is testing

Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma

Who this might be right for
Relapsed/Refractory Classical Hodgkin Lymphoma
National Cancer Center, Korea 30
Not applicableLooking for participantsNCT06822855
What this trial is testing

Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin LymphomaClassical Hodgkin Lymphoma RecurrentClassical Hodgkin Lymphoma Refractory
Azienda USL Reggio Emilia - IRCCS 755
Early research (Phase 1)UnknownNCT03657381
What this trial is testing

Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520

Who this might be right for
Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma
Shandong New Time Pharmaceutical Co., LTD 75
Testing effectiveness (Phase 2)UnknownNCT04624984
What this trial is testing

PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

Who this might be right for
Classical Hodgkin LymphomaRefractory or Relapsed Classical Hodgkin Lymphoma
Sun Yat-sen University 42
Early research (Phase 1)UnknownNCT03374007
What this trial is testing

Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma

Who this might be right for
Advanced Solid TumorRecurrent Solid TumorLymphoma+1 more
Genor Biopharma Co., Ltd. 72
Testing effectiveness (Phase 2)WithdrawnNCT00129753
What this trial is testing

Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease

Who this might be right for
Hodgkin's DiseaseLymphoma
M.D. Anderson Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT04268706
What this trial is testing

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Who this might be right for
Hodgkin Lymphoma, AdultHodgkin Disease RecurrentHodgkin Disease Refractory+1 more
Tessa Therapeutics 97
Early research (Phase 1)Active Not RecruitingNCT02153580
What this trial is testing

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Who this might be right for
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin LymphomaB-Cell Prolymphocytic LeukemiaHigh Grade B-Cell Lymphoma, Not Otherwise Specified+10 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Study completedNCT04074746
What this trial is testing

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Who this might be right for
Recurrent Anaplastic Large Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Classic Hodgkin Lymphoma+7 more
M.D. Anderson Cancer Center 45
Early research (Phase 1)Study completedNCT00020579
What this trial is testing

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Who this might be right for
Cancer
National Institutes of Health Clinical Center (CC) 75
Early research (Phase 1)Study completedNCT00646139
What this trial is testing

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Who this might be right for
LymphomaLymphoproliferative DisorderSmall Intestine Cancer+1 more
Roswell Park Cancer Institute 7
Load More Results
37